Key facts
- Notable investors include Ningqian Investment, Wotu Investment.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Changhe Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Changhe Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Changhe Biotech
Developer of molecular diagnostic technologies intended for oncology treatment planning. The company utilizes high-throughput sequencing, multi-gene panel analysis, and bioinformatics pipelines to detect mutations, copy number variations, and microsatellite instability from tumor tissue or blood samples, serving the precision medicine market to deliver individualized therapeutic recommendations and prognostic insights for colorectal cancer patients through clinically validated genomic profiling.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Website
- chbio.com.cn/
- Ownership
- Privately Held (backing)
Changhe Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Changhe Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Changhe Biotech in its N-PORT filings yet. We sweep new filings monthly.